Search

Sartorius Stedim Biotech.

Closed

SectorFinance

167.9 -1.06

Overview

Share price change

24h

Current

Min

167.6

Max

168.2

Key metrics

By Trading Economics

Income

4.9M

93M

Sales

4.2M

766M

P/E

Sector Avg

54.053

18.576

EPS

1.29

Dividend yield

0.41

Profit margin

12.146

Employees

10,477

EBITDA

9.2M

240M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+37.97% upside

Dividends

By Acuity

Dividend yield

Sector Avg

0.41%

4.62%

Next Earnings

22 Oct 2026

Market Stats

By TradingEconomics

Market Cap

-1.7B

16B

Previous open

168.96

Previous close

167.9

News Sentiment

By Acuity

23%

77%

51 / 438 Finance

Sartorius Stedim Biotech. Chart

Past performance is not a reliable indicator of future results.

Related News

31 Jul 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

31 Jul 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

31 Jul 2026, 23:51 UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

31 Jul 2026, 23:46 UTC

News

3M shares declined in after-market trading amid concerns over insider selling by EVP Kevin H. Rhodes, who sold $1.3 million worth of stock.

31 Jul 2026, 23:41 UTC

Social Media
News
Correlated Moves

Goldman Sachs shares declined in after-market trading amid broader market turmoil and hedge fund degrossing linked to losses on leveraged AI investments.

31 Jul 2026, 23:41 UTC

News

JPMorgan Chase & Co. shares are lower in after-market trading following a note highlighting ongoing market rotation and challenges from rising long-term Treasury yields.

31 Jul 2026, 23:36 UTC

News

Carvana shares declined in after-market trading following Citigroup's price target cut to $90, amid broader market weakness from Apple's disappointing guidance.

31 Jul 2026, 23:36 UTC

News

DoorDash Inc shares are lower in after-market trading amid concerns over order demand and rising fuel prices ahead of its upcoming Q2 earnings report.

31 Jul 2026, 23:36 UTC

News

Warner Bros Discovery shares are lower in after-market trading amid concerns over job losses tied to Paramount's $81 billion acquisition and its extended offer deadlines.

31 Jul 2026, 23:36 UTC

News

Bloom Energy Corp shares are lower in after-market trading amid a class action lawsuit alleging securities fraud related to its reliance on Chinese scandium.

31 Jul 2026, 23:32 UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

31 Jul 2026, 23:31 UTC

News

KKR & Co Inc reported record Q2 revenue of $6.31 billion, yet shares are trading lower in after-market hours following earlier volatility.

31 Jul 2026, 23:26 UTC

News

Norwegian Cruise Line shares are lower in after-market hours following Citigroup's price target cut to $22 amid ongoing valuation concerns.

31 Jul 2026, 23:26 UTC

News

NOW Inc shares are higher after market hours, reflecting positive sentiment in the trading companies sector and ongoing demand for energy products.

31 Jul 2026, 23:26 UTC

News

Pomerantz LLP has filed a class action lawsuit against Verra Mobility Corp for securities fraud, contributing to lower after-market trading for the company.

31 Jul 2026, 23:26 UTC

News

Roblox Corp's stock is lower in after-market hours following UBS's price target cut to $45 and a class action lawsuit announcement by Pomerantz LLP.

31 Jul 2026, 23:16 UTC

News

KBR Inc. reported second-quarter revenue of $1.98 billion and reaffirmed full-year guidance, but shares are trading lower in after-market hours.

31 Jul 2026, 23:16 UTC

News

Tractor Supply Co reported second-quarter revenue of $4.54 billion, missing expectations. Shares are trading lower in after-market hours following the earnings release.

31 Jul 2026, 23:16 UTC

News

PBF Energy shares are lower in after-market hours following Citigroup's Neutral rating and price target increase to $74. The stock remains above its 20-day moving average.

31 Jul 2026, 23:16 UTC

News

Huntington Ingalls Industries shares rise in after-market trading following strong Q2 results, with sales of $3.42 billion and a non-GAAP profit of $5.27 per share.

31 Jul 2026, 23:16 UTC

News

Shares of GE Healthcare Technologies are lower in after-market trading following UBS's Neutral rating and a price target increase to $73.

31 Jul 2026, 23:16 UTC

News

Gilead Sciences shares are higher in after-market trading amid market fluctuations. Accessibility challenges for lenacapavir in Latin America may impact potential sales.

31 Jul 2026, 23:16 UTC

News

Alnylam Pharmaceuticals reported Q2 2026 net product revenue of $1.2 billion, driven by strong AMVUTTRA uptake. Shares rose slightly in after-market trading.

31 Jul 2026, 23:11 UTC

News

Lockheed Martin secured a $107.29 million Navy contract for VH-92A rotor blades, with shares trading higher in after-market hours.

31 Jul 2026, 23:06 UTC

News

Hawaiian Electric Industries has signed a 30-year power purchase agreement, with shares trading higher in after-market hours.

31 Jul 2026, 23:06 UTC

News

General Electric Co shares are lower in after-market trading, despite recent analyst upgrades and reaffirmed buy ratings for GE Aerospace.

31 Jul 2026, 23:06 UTC

News

Regeneron Pharmaceuticals shares declined in after-market hours following a class action lawsuit alleging securities fraud related to its Phase III study modifications.

31 Jul 2026, 23:06 UTC

News

Permian Resources Corp shares are trading higher in after-market hours following recognition as a top investment choice by Yahoo Finance, citing strong financial performance.

31 Jul 2026, 23:06 UTC

Social Media
News

NVIDIA shares are lower in after-market trading despite strong fiscal first-quarter results, with revenues of $81.6 billion and record data center sales.

31 Jul 2026, 23:06 UTC

News

Coinbase Global reported a record share of global crypto trading volume but also a significant net loss. Shares are roughly flat in after-market trading.

Peer Comparison

Price change

Sartorius Stedim Biotech. Forecast

Price Target

By TipRanks

37.97% upside

12 Months Forecast

Average 230 EUR  37.97%

High 260 EUR

Low 210 EUR

Based on 5 Wall Street analysts offering 12 month price targets forSartorius Stedim Biotech. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

4

Buy

1

Hold

0

Sell

Sentiment

By Acuity

51 / 438 Finance

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat